Skip to main content

Advertisement

Log in

Ewing’s Sarcoma: Standard and Experimental Treatment Options

  • Bone Cancer
  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion statement

Ewing sarcoma family tumors (EWS), which include classic Ewing’s sarcoma in addition to primitive neuroectodermal tumor and Askin tumor, are the second most common variety of primary bone cancer to afflict adolescents and young adults. Multi-disciplinary care incorporating advances in diagnosis, surgery, chemotherapy, and radiation has substantially improved the survival rate of patients with localized Ewing sarcoma to nearly 70%. Unfortunately, those advances have not significantly changed the long-term outcome for those with metastatic or recurrent disease; 5-year survival remains less than 25%. This apparent therapeutic plateau exists despite extensive effort during the last four decades to optimize the efficacy of cytotoxic chemotherapy through combination of chemotherapies of mechanistically diverse action, dose-dense scheduling (provided as frequently as every 2 weeks), increased adjuvant treatment duration, and higher dosage per cycle (facilitated with parallel strides in supportive care incorporating growth factors). As has already occurred for malignancies such as breast or colon cancer, the “-omics-based” revolution has enhanced our understanding of the molecular changes responsible for Ewing’s tumor formation and identified a number of potential targets (such as IGF-1R or mTOR) amenable to biological therapy. It has also created both a challenge and an opportunity to develop predictive biomarkers capable of selecting patients most likely to benefit from targeted therapy. In this review, we discuss current standard-of-care for patients with Ewing’s sarcoma and highlight the most promising experimental therapies in early-phase clinical trials.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recomended Reading

  1. Herzog, C.E., Overview of sarcomas in the adolescent and young adult population. J Pediatr Hematol Oncol, 2005. 27(4): p. 215-8. doi:10.1097/01.mph.0000161762.53175.e4.

    Article  PubMed  Google Scholar 

  2. Ewing, J., Classics in oncology. Diffuse endothelioma of bone. James Ewing. Proceedings of the New York Pathological Society, 1921. CA Cancer J Clin, 1972. 22(2): p. 95-8. doi:10.3322/canjclin.22.2.95.

    Article  PubMed  CAS  Google Scholar 

  3. Angervall, L. and F.M. Enzinger, Extraskeletal neoplasm resembling Ewing’s sarcoma. Cancer, 1975. 36(1): p. 240-51. doi:10.1002/1097-0142(197507)36:1<240::AID-CNCR2820360127>3.0.CO;2-H.

    Article  PubMed  CAS  Google Scholar 

  4. Askin, F.B., et al., Malignant small cell tumor of the thoracopulmonary region in childhood: a distinctive clinicopathologic entity of uncertain histogenesis. Cancer, 1979. 43(6): p. 2438-51. doi:10.1002/1097-0142(197906)43:6<2438::AID-CNCR2820430640>3.0.CO;2-9.

    Article  PubMed  CAS  Google Scholar 

  5. Jaffe, R., et al., The neuroectodermal tumor of bone. Am J Surg Pathol, 1984. 8(12): p. 885-98. doi:10.1097/00000478-198412000-00001.

    Article  PubMed  CAS  Google Scholar 

  6. de Alava, E. and W.L. Gerald, Molecular biology of the Ewing’s sarcoma/primitive neuroectodermal tumor family. J Clin Oncol, 2000. 18(1): p. 204-13.

    PubMed  Google Scholar 

  7. Seddon, B.M. and J.S. Whelan, Emerging chemotherapeutic strategies and the role of treatment stratification in Ewing sarcoma. Paediatr Drugs, 2008. 10(2): p. 93-105. doi:10.2165/00148581-200810020-00004.

    Article  PubMed  Google Scholar 

  8. Kim, S.Y., M. Tsokos, and L.J. Helman, Dilemmas associated with congenital ewing sarcoma family tumors. J Pediatr Hematol Oncol, 2008. 30(1): p. 4-7. doi:10.1097/MPH.0b013e31815cf71f.

    Article  PubMed  Google Scholar 

  9. Folpe, A.L., et al., Morphologic and immunophenotypic diversity in Ewing family tumors: a study of 66 genetically confirmed cases. Am J Surg Pathol, 2005. 29(8): p. 1025-33.

    PubMed  Google Scholar 

  10. Lazar, A., et al., Molecular diagnosis of sarcomas: chromosomal translocations in sarcomas. Arch Pathol Lab Med, 2006. 130(8): p. 1199-207.

    PubMed  CAS  Google Scholar 

  11. Khoury, J.D., Ewing sarcoma family of tumors: a model for the new era of integrated laboratory diagnostics. Expert Rev Mol Diagn, 2008. 8(1): p. 97-105. doi:10.1586/14737159.8.1.97.

    Article  PubMed  CAS  Google Scholar 

  12. Avigad, S., et al., The predictive potential of molecular detection in the nonmetastatic Ewing family of tumors. Cancer, 2004. 100(5): p. 1053-8. doi:10.1002/cncr.20059.

    Article  PubMed  Google Scholar 

  13. Zoubek, A., et al., Does expression of different EWS chimeric transcripts define clinically distinct risk groups of Ewing tumor patients? J Clin Oncol, 1996. 14(4): p. 1245-51.

    PubMed  CAS  Google Scholar 

  14. de Alava, E., et al., EWS-FLI1 fusion transcript structure is an independent determinant of prognosis in Ewing’s sarcoma. J Clin Oncol, 1998. 16(4): p. 1248-55.

    PubMed  Google Scholar 

  15. Lin, P.P., et al., Differential transactivation by alternative EWS-FLI1 fusion proteins correlates with clinical heterogeneity in Ewing’s sarcoma. Cancer Res, 1999. 59(7): p. 1428-32.

    PubMed  CAS  Google Scholar 

  16. Ludwig, J.A., Ewing sarcoma: historical perspectives, current state-of-the-art, and opportunities for targeted therapy in the future. Curr Opin Oncol, 2008. 20(4): p. 412-8.

    Article  PubMed  Google Scholar 

  17. Falk, S. and M. Alpert, Five-year survival of patients with Ewing’s sarcoma. Surg Gynecol Obstet, 1967. 124(2): p. 319-24.

    PubMed  CAS  Google Scholar 

  18. Sutow, W.W. and M.P. Sullivan, Cyclophosphamide therapy in children with Ewing’s sarcoma. Cancer Chemother Rep, 1962. 23: p. 55-60.

    PubMed  CAS  Google Scholar 

  19. Pinkel, D., Cyclophosphamide in children with cancer. Cancer, 1962. 15: p. 42-9. doi:10.1002/1097-0142(196201/02)15:1<42::AID-CNCR2820150107>3.0.CO;2-D.

    Article  PubMed  CAS  Google Scholar 

  20. Johnson, R. and S.R. Humphreys, Past failures and future possibilities in Ewing’s sarcoma. Experimental and preliminary clinical results. Cancer, 1969. 23(1): p. 161-6. doi:10.1002/1097-0142(196901)23:1<161::AID-CNCR2820230121>3.0.CO;2-L.

    Article  PubMed  CAS  Google Scholar 

  21. Senyszyn, J.J., R.E. Johnson, and R.E. Curran, Treatment of metastatic Ewing’s sarcoma with actinomycin D (NSC-3053). Cancer Chemother Rep, 1970. 54(2): p. 103-7.

    PubMed  CAS  Google Scholar 

  22. Hustu, H.O., D. Pinkel, and C.B. Pratt, Treatment of clinically localized Ewing’s sarcoma with radiotherapy and combination chemotherapy. Cancer, 1972. 30(6): p. 1522-7. doi:10.1002/1097-0142(197212)30:6<1522::AID-CNCR2820300617>3.0.CO;2-J.

    Article  PubMed  CAS  Google Scholar 

  23. Oldham, R.K. and T.C. Pomeroy, Treatment of Ewing’s sarcoma with adriamycin (NSC-123127). Cancer Chemother Rep, 1972. 56(5): p. 635-9.

    PubMed  CAS  Google Scholar 

  24. Rosen, G., et al., Proceedings: Disease-free survival in children with Ewing’s sarcoma treated with radiation therapy and adjuvant four-drug sequential chemotherapy. Cancer, 1974. 33(2): p. 384-93. doi:10.1002/1097-0142(197402)33:2<384::AID-CNCR2820330213>3.0.CO;2-T.

    Article  PubMed  CAS  Google Scholar 

  25. Hayes, F.A., et al., Therapy for localized Ewing’s sarcoma of bone. J Clin Oncol, 1989. 7(2): p. 208-13.

    PubMed  CAS  Google Scholar 

  26. Jurgens, H., et al., Multidisciplinary treatment of primary Ewing’s sarcoma of bone. A 6-year experience of a European Cooperative Trial. Cancer, 1988. 61(1): p. 23-32. doi:10.1002/1097-0142(19880101)61:1<23::AID-CNCR2820610106>3.0.CO;2-M.

    Article  PubMed  CAS  Google Scholar 

  27. Razek, A., et al., Intergroup Ewing’s Sarcoma Study: local control related to radiation dose, volume, and site of primary lesion in Ewing’s sarcoma. Cancer, 1980. 46(3): p. 516-21. doi:10.1002/1097-0142(19800801)46:3<516::AID-CNCR2820460316>3.0.CO;2-K.

    Article  PubMed  CAS  Google Scholar 

  28. Grier, H.E., et al., Addition of ifosfamide and etoposide to standard chemotherapy for Ewing’s sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med, 2003. 348(8): p. 694-701. doi:10.1056/NEJMoa020890.

    Article  PubMed  CAS  Google Scholar 

  29. Paulussen, M., et al., Ewing’s sarcoma of the bone: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol, 2008. 19 Suppl 2: p. ii97-8. doi:10.1093/annonc/mdn103.

    Article  PubMed  Google Scholar 

  30. Womer RB, West DC, Krailo MD, Dickman PS, Pawel B, for the Children’s Oncology Group AEWS0031 Committee: Randomized comparison of every-two-week v. every-three-week chemotherapy in Ewing sarcoma family tumors (ESFT). J Clin Oncol 2008, 26(May 20 suppl; abstr 10504)

  31. Ferrari, S, et al.: Response to high-dose ifosfamide in patients with advanced/recurrent Ewing sarcoma. Pediatr Blood Cancer 2009

    Article  PubMed  CAS  Google Scholar 

  32. Laskar, S., et al., Post-operative radiotherapy for Ewing sarcoma: when, how and how much? Pediatr Blood Cancer, 2008. 51(5): p. 575-80. doi:10.1002/pbc.21657.

    Article  PubMed  CAS  Google Scholar 

  33. Indelicato, D.J., et al., Definitive radiotherapy for ewing tumors of extremities and pelvis: long-term disease control, limb function, and treatment toxicity. Int J Radiat Oncol Biol Phys, 2008. 72(3): p. 871-7. doi:10.1016/j.ijrobp.2008.02.023.

    PubMed  Google Scholar 

  34. Indelicato, D.J., et al., Long-term clinical and functional outcomes after treatment for localized Ewing’s tumor of the lower extremity. Int J Radiat Oncol Biol Phys, 2008. 70(2): p. 501-9. doi:10.1016/j.ijrobp.2007.06.032.

    PubMed  Google Scholar 

  35. Schuck, A., et al., Local therapy in localized Ewing tumors: results of 1058 patients treated in the CESS 81, CESS 86, and EICESS 92 trials. Int J Radiat Oncol Biol Phys, 2003. 55(1): p. 168-77. doi:10.1016/S0360-3016(02)03797-5.

    Article  PubMed  Google Scholar 

  36. Bacci, G., et al., Long-term outcome for patients with non-metastatic Ewing’s sarcoma treated with adjuvant and neoadjuvant chemotherapies. 402 patients treated at Rizzoli between 1972 and 1992. Eur J Cancer, 2004. 40(1): p. 73-83. doi:10.1016/j.ejca.2003.08.022.

    Article  PubMed  CAS  Google Scholar 

  37. Donaldson, S.S., et al., A multidisciplinary study investigating radiotherapy in Ewing’s sarcoma: end results of POG #8346. Pediatric Oncology Group. Int J Radiat Oncol Biol Phys, 1998. 42(1): p. 125-35. doi:10.1016/S0360-3016(98)00191-6.

    PubMed  CAS  Google Scholar 

  38. Krasin, M.J., et al., Definitive irradiation in multidisciplinary management of localized Ewing sarcoma family of tumors in pediatric patients: outcome and prognostic factors. Int J Radiat Oncol Biol Phys, 2004. 60(3): p. 830-8. doi:10.1016/j.ijrobp.2004.04.006.

    PubMed  Google Scholar 

  39. Donaldson, S.S., Ewing sarcoma: radiation dose and target volume. Pediatr Blood Cancer, 2004. 42(5): p. 471-6. doi:10.1002/pbc.10472.

    Article  PubMed  Google Scholar 

  40. Cotterill, S.J., et al., Prognostic factors in Ewing’s tumor of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing’s Sarcoma Study Group. J Clin Oncol, 2000. 18(17): p. 3108-14.

    PubMed  CAS  Google Scholar 

  41. Kolb, E.A., et al., Long-term event-free survival after intensive chemotherapy for Ewing’s family of tumors in children and young adults. J Clin Oncol, 2003. 21(18): p. 3423-30. doi:10.1200/JCO.2003.10.033.

    Article  PubMed  CAS  Google Scholar 

  42. Sinkovics, J.G., et al., Ewing sarcoma: its course and treatment in 50 adult patients. Oncology, 1980. 37(2): p. 114-9.

    Article  PubMed  CAS  Google Scholar 

  43. Siegel, R.D., L.M. Ryan, and K.H. Antman, Adults with Ewing’s sarcoma. An analysis of 16 patients at the Dana-Farber Cancer Institute. Am J Clin Oncol, 1988. 11(6): p. 614-7. doi:10.1097/00000421-198812000-00003.

    Article  PubMed  CAS  Google Scholar 

  44. Picci, P., et al., Chemotherapy-induced tumor necrosis as a prognostic factor in localized Ewing’s sarcoma of the extremities. J Clin Oncol, 1997. 15(4): p. 1553-9.

    PubMed  CAS  Google Scholar 

  45. Verrill, M.W., et al., Ewing’s sarcoma and primitive neuroectodermal tumor in adults: are they different from Ewing’s sarcoma and primitive neuroectodermal tumor in children? J Clin Oncol, 1997. 15(7): p. 2611-21.

    PubMed  CAS  Google Scholar 

  46. Fizazi, K., et al., Ewing’s family of tumors in adults: multivariate analysis of survival and long-term results of multimodality therapy in 182 patients. J Clin Oncol, 1998. 16(12): p. 3736-43.

    PubMed  CAS  Google Scholar 

  47. Bacci, G., et al., Adjuvant and neoadjuvant chemotherapy for Ewing sarcoma family tumors in patients aged between 40 and 60: report of 35 cases and comparison of results with 586 younger patients treated with the same protocols in the same years. Cancer, 2007. 109(4): p. 780-6. doi:10.1002/cncr.22456.

    Article  PubMed  CAS  Google Scholar 

  48. Pieper, S., et al., Ewing’s tumors over the age of 40: a retrospective analysis of 47 patients treated according to the International Clinical Trials EICESS 92 and EURO-E.W.I.N.G. 99. Onkologie, 2008. 31(12): p. 657-63. doi:10.1159/000165361.

    Article  PubMed  Google Scholar 

  49. Paulussen M, Ahrens S, Juergens HF: Cure rates in Ewing tumor patients aged over 15 years are better in pediatric oncology units. Results of GPOH CESS/EICESS studies. ASCO 2003 Annual Meeting 2003

  50. Dyke, J.P., et al., Osteogenic and Ewing sarcomas: estimation of necrotic fraction during induction chemotherapy with dynamic contrast-enhanced MR imaging. Radiology, 2003. 228(1): p. 271-8. doi:10.1148/radiol.2281011651.

    Article  PubMed  Google Scholar 

  51. Leavey, P.J. and A.B. Collier, Ewing sarcoma: prognostic criteria, outcomes and future treatment. Expert Rev Anticancer Ther, 2008. 8(4): p. 617-24. doi:10.1586/14737140.8.4.617.

    Article  PubMed  CAS  Google Scholar 

  52. Esiashvili, N., M. Goodman, and R.B. Marcus, Jr., Changes in incidence and survival of Ewing sarcoma patients over the past 3 decades: Surveillance Epidemiology and End Results data. J Pediatr Hematol Oncol, 2008. 30(6): p. 425-30. doi:10.1097/MPH.0b013e31816e22f3.

    Article  PubMed  Google Scholar 

  53. Leavey, P.J., et al., Prognostic factors for patients with Ewing sarcoma (EWS) at first recurrence following multi-modality therapy: A report from the Children’s Oncology Group. Pediatr Blood Cancer, 2008. 51(3): p. 334-8. doi:10.1002/pbc.21618.

    Article  PubMed  Google Scholar 

  54. Hustu, H.O., et al., Treatment of Ewing’s sarcoma with concurrent radiotherapy and chemotherapy. J Pediatr, 1968. 73(2): p. 249-51. doi:10.1016/S0022-3476(68)80078-2.

    Article  PubMed  CAS  Google Scholar 

  55. Saylors, R.L., 3rd, et al., Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group phase II study. J Clin Oncol, 2001. 19(15): p. 3463-9.

    PubMed  CAS  Google Scholar 

  56. Hunold, A., et al., Topotecan and cyclophosphamide in patients with refractory or relapsed Ewing tumors. Pediatr Blood Cancer, 2006. 47(6): p. 795-800. doi:10.1002/pbc.20719.

    Article  PubMed  Google Scholar 

  57. Anderson, P., et al., Novel bone cancer drugs: investigational agents and control paradigms for primary bone sarcomas (Ewing’s sarcoma and osteosarcoma). Expert Opin Investig Drugs, 2008. 17(11): p. 1703-15. doi:10.1517/13543784.17.11.1703.

    Article  PubMed  CAS  Google Scholar 

  58. Wagner, L.M., et al., Phase I trial of temozolomide and protracted irinotecan in pediatric patients with refractory solid tumors. Clin Cancer Res, 2004. 10(3): p. 840-8. doi:10.1158/1078-0432.CCR-03-0175.

    Article  PubMed  CAS  Google Scholar 

  59. Wagner, L.M., et al., Temozolomide and intravenous irinotecan for treatment of advanced Ewing sarcoma. Pediatr Blood Cancer, 2007. 48(2): p. 132-9. doi:10.1002/pbc.20697.

    Article  PubMed  Google Scholar 

  60. Kushner, B.H., et al., Irinotecan plus temozolomide for relapsed or refractory neuroblastoma. J Clin Oncol, 2006. 24(33): p. 5271-6. doi:10.1200/JCO.2006.06.7272.

    Article  PubMed  CAS  Google Scholar 

  61. Maki, R.G., et al., Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]. J Clin Oncol, 2007. 25(19): p. 2755-63. doi:10.1200/JCO.2006.10.4117.

    Article  PubMed  CAS  Google Scholar 

  62. Ludwig, J.A. and J.N. Weinstein, Biomarkers in cancer staging, prognosis and treatment selection. Nat Rev Cancer, 2005. 5(11): p. 845-56. doi:10.1038/nrc1739.

    Article  PubMed  CAS  Google Scholar 

  63. Schuetze, S.M., Chemotherapy in the management of osteosarcoma and Ewing’s sarcoma. J Natl Compr Canc Netw, 2007. 5(4): p. 449-55.

    PubMed  CAS  Google Scholar 

  64. Ladenstein, R., et al., Impact of megatherapy in children with high-risk Ewing’s tumours in complete remission: a report from the EBMT Solid Tumour Registry. Bone Marrow Transplant, 1995. 15(5): p. 697-705.

    PubMed  CAS  Google Scholar 

  65. Paulussen, M., et al., Primary metastatic (stage IV) Ewing tumor: survival analysis of 171 patients from the EICESS studies. European Intergroup Cooperative Ewing Sarcoma Studies. Ann Oncol, 1998. 9(3): p. 275-81. doi:10.1023/A:1008208511815.

    Article  PubMed  CAS  Google Scholar 

  66. Burdach, S., et al., Allogeneic and autologous stem-cell transplantation in advanced Ewing tumors. An update after long-term follow-up from two centers of the European Intergroup study EICESS. Stem-Cell Transplant Programs at Dusseldorf University Medical Center, Germany and St. Anna Kinderspital, Vienna, Austria. Ann Oncol, 2000. 11(11): p.1451-62. doi:10.1023/A:1026539908115.

    Article  PubMed  CAS  Google Scholar 

  67. Meyers, P.A., et al., High-dose melphalan, etoposide, total-body irradiation, and autologous stem-cell reconstitution as consolidation therapy for high-risk Ewing’s sarcoma does not improve prognosis. J Clin Oncol, 2001. 19(11): p. 2812-20.

    PubMed  CAS  Google Scholar 

  68. Burdach, S., et al., High-dose therapy for patients with primary multifocal and early relapsed Ewing’s tumors: results of two consecutive regimens assessing the role of total-body irradiation. J Clin Oncol, 2003. 21(16): p. 3072-8. doi:10.1200/JCO.2003.12.039.

    Article  PubMed  CAS  Google Scholar 

  69. Bhatia, S., et al., Therapy-related myelodysplasia and acute myeloid leukemia after Ewing sarcoma and primitive neuroectodermal tumor of bone: A report from the Children’s Oncology Group. Blood, 2007. 109(1): p. 46-51. doi:10.1182/blood-2006-01-023101.

    Article  PubMed  CAS  Google Scholar 

  70. Hosono A, et al.: Segregated graft-versus-tumor effect between CNS and non-CNS lesions of Ewing’s sarcoma family of tumors. Bone Marrow Transplant 2008

    Article  PubMed  CAS  Google Scholar 

  71. Bolontrade, M.F., R.R. Zhou, and E.S. Kleinerman, Vasculogenesis Plays a Role in the Growth of Ewing’s Sarcoma in Vivo. Clin Cancer Res, 2002. 8(11): p. 3622-7.

    PubMed  Google Scholar 

  72. Fuchs, B., C.Y. Inwards, and R. Janknecht, Vascular endothelial growth factor expression is up-regulated by EWS-ETS oncoproteins and Sp1 and may represent an independent predictor of survival in Ewing’s sarcoma. Clin Cancer Res, 2004. 10(4): p. 1344-53. doi:10.1158/1078-0432.CCR-03-0038.

    Article  PubMed  CAS  Google Scholar 

  73. Garcia-Carbonero, R., et al., Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy. J Clin Oncol, 2004. 22(8): p. 1480-90. doi:10.1200/JCO.2004.02.098.

    Article  PubMed  CAS  Google Scholar 

  74. Sakai, R., et al., Additional antitumor ecteinascidins from a Caribbean tunicate: crystal structures and activities in vivo. Proc Natl Acad Sci U S A, 1992. 89(23): p. 11456-60. doi:10.1073/pnas.89.23.11456.

    Article  PubMed  CAS  Google Scholar 

  75. Martinez, N., et al., Transcriptional signature of Ecteinascidin 743 (Yondelis, Trabectedin) in human sarcoma cells explanted from chemo-naive patients. Mol Cancer Ther, 2005. 4(5): p. 814-23. doi:10.1158/1535-7163.MCT-04-0316.

    Article  PubMed  CAS  Google Scholar 

  76. Kovar, H., et al., EWS/FLI-1 antagonists induce growth inhibition of Ewing tumor cells in vitro. Cell Growth Differ, 1996. 7(4): p. 429-37.

    PubMed  CAS  Google Scholar 

  77. Tanaka, K., et al., EWS-Fli1 antisense oligodeoxynucleotide inhibits proliferation of human Ewing’s sarcoma and primitive neuroectodermal tumor cells. J Clin Invest, 1997. 99(2): p. 239-47. doi:10.1172/JCI119152.

    Article  PubMed  CAS  Google Scholar 

  78. Toretsky, J.A., et al., Inhibition of EWS-FLI-1 fusion protein with antisense oligodeoxynucleotides. J Neurooncol, 1997. 31(1-2): p. 9-16. doi:10.1023/A:1005716926800.

    Article  PubMed  CAS  Google Scholar 

  79. Lambert, G., et al., EWS fli-1 antisense nanocapsules inhibits ewing sarcoma-related tumor in mice. Biochem Biophys Res Commun, 2000. 279(2): p. 401-6. doi:10.1006/bbrc.2000.3963.

    Article  PubMed  CAS  Google Scholar 

  80. Stegmaier, K., et al., Signature-based small molecule screening identifies cytosine arabinoside as an EWS/FLI modulator in Ewing sarcoma. PLoS Med, 2007. 4(4): p. e122. doi:10.1371/journal.pmed.0040122.

    Article  PubMed  CAS  Google Scholar 

  81. DuBois, S.G., et al., Phase II study of intermediate-dose cytarabine in patients with relapsed or refractory Ewing sarcoma: a report from the Children’s Oncology Group. Pediatr Blood Cancer, 2009. 52(3): p. 324-7. doi:10.1002/pbc.21822.

    Article  PubMed  Google Scholar 

  82. Rikhof B, et al.: The insulin-like growth factor system and sarcomas. J Pathol 2008

    Article  PubMed  CAS  Google Scholar 

  83. Toretsky, J.A., et al., The insulin-like growth factor-I receptor is required for EWS/FLI-1 transformation of fibroblasts. J Biol Chem, 1997. 272(49): p. 30822-7. doi:10.1074/jbc.272.49.30822.

    Article  PubMed  CAS  Google Scholar 

  84. Scotlandi, K., et al., Insulin-like growth factor I receptor-mediated circuit in Ewing’s sarcoma/peripheral neuroectodermal tumor: a possible therapeutic target. Cancer Res, 1996. 56(20): p. 4570-4.

    PubMed  CAS  Google Scholar 

  85. Prieur, A., et al., EWS/FLI-1 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3. Mol Cell Biol, 2004. 24(16): p. 7275-83. doi:10.1128/MCB.24.16.7275-7283.2004.

    Article  PubMed  CAS  Google Scholar 

  86. Benini, S., et al., Contribution of MEK/MAPK and PI3-K signaling pathway to the malignant behavior of Ewing’s sarcoma cells: therapeutic prospects. Int J Cancer, 2004. 108(3): p. 358-66. doi:10.1002/ijc.11576.

    Article  PubMed  CAS  Google Scholar 

  87. Manara, M.C., et al., Preclinical in vivo study of new insulin-like growth factor-I receptor–specific inhibitor in Ewing’s sarcoma. Clin Cancer Res, 2007. 13(4): p. 1322-30. doi:10.1158/1078-0432.CCR-06-1518.

    Article  PubMed  CAS  Google Scholar 

  88. Hurtubise, A., M.L. Bernstein, and R.L. Momparler, Preclinical evaluation of the antineoplastic action of 5-aza-2’-deoxycytidine and different histone deacetylase inhibitors on human Ewing’s sarcoma cells. Cancer Cell Int, 2008. 8: p. 16. doi:10.1186/1475-2867-8-16.

    Article  PubMed  CAS  Google Scholar 

  89. Dalal S, Burchill SA: Preclinical evaluation of vascular-disrupting agents in Ewing’s sarcoma family of tumours. Eur J Cancer 2009

    Article  PubMed  CAS  Google Scholar 

  90. Zhou, Z., et al., Suppression of Ewing’s sarcoma tumor growth, tumor vessel formation, and vasculogenesis following anti vascular endothelial growth factor receptor-2 therapy. Clin Cancer Res, 2007. 13(16): p. 4867-73. doi:10.1158/1078-0432.CCR-07-0133.

    Article  PubMed  CAS  Google Scholar 

  91. Schaefer KL, et al.: Microarray analysis of Ewing’s sarcoma family of tumours reveals characteristic gene expression signatures associated with metastasis and resistance to chemotherapy. Eur J Cancer 2008

    PubMed  CAS  Google Scholar 

  92. Uren, A., et al., Wnt/Frizzled signaling in Ewing sarcoma. Pediatr Blood Cancer, 2004. 43(3): p. 243-9. doi:10.1002/pbc.20124.

    Article  PubMed  Google Scholar 

  93. Zwerner JP, et al.: The EWS/FLI1 oncogenic transcription factor deregulates GLI1. Oncogene 2007

    Article  PubMed  CAS  Google Scholar 

  94. Ordonez, J.L., et al., Targeting sarcomas: therapeutic targets and their rational. Semin Diagn Pathol, 2008. 25(4): p. 304-16. doi:10.1053/j.semdp.2008.07.005.

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

We thank Kim-Anh Vu for the graphic design. Grant support: UT MD Anderson Cancer Center Intra-mural funding (J.A.L.), UT MD Anderson Physician Scientist program (A.J.L.) and Jeremy Rosen Memorial fund (P.A.).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Joseph A. Ludwig MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Subbiah, V., Anderson, P., Lazar, A.J. et al. Ewing’s Sarcoma: Standard and Experimental Treatment Options. Curr. Treat. Options in Oncol. 10, 126–140 (2009). https://doi.org/10.1007/s11864-009-0104-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11864-009-0104-6

Navigation